Navigation Links
Imaging Diagnostic Systems CT Laser Mammography (CTLM(R)) System Featured at the 94th Annual Radiological Society of North America (RSNA) Conference
Date:12/1/2008

FORT LAUDERDALE, Fla., Dec. 1 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS), a pioneer in laser optical breast imaging, announced today that a recent study on CTLM is one of the featured scientific abstracts at RSNA 2008, November 30th - December 5th. Dr. Jin Qi, a radiologist at the Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, was selected for her paper, "CTLM as an Adjunct to Mammography in the Diagnosis of Patients with Dense Breasts." Dr. Qi is attending RSNA with IDSI and will be present at the company's exhibit.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )

Her study, which evaluated CTLM as an adjunct to mammography in women with heterogeneously or extremely dense breast tissue, found that CTLM could successfully distinguish malignant from benign lesions in dense breasts. The system's imaging capabilities were not affected by tissue density in breasts and could provide information about angiogenesis in malignant and benign breast lesions.

Women who were scheduled for biopsy were first evaluated with mammography to classify breast density and then examined by the CTLM system. The CTLM examination was performed subsequently with mammography. The findings were then compared to mammography alone, the CTLM system alone, and CTLM and mammography adjunctively. Sensitivity, specificity, and positive predictive values were calculated by using standard methods. Among the extremely dense breast patient population, the sensitivity of mammography alone was 34.40%. CTLM alone resulted in a sensitivity of 74.40%, and mammography plus CTLM produced a sensitivity of 81.57%. The specificity of mammography alone was 90.48%; CTLM alone, 71.00%; and mammography plus CTLM was 72.22%.

In the heterogeneously dense breast patient population, the sensitivity of mammography alone was 68.29%; CTLM alone was 85%; and mammography plus CTLM resulted in a sensitivity of 95.34%. The specificity of mammography alone was 85%. CTLM alone was 61% and mammography plus CTLM was 55.26%.

"When CTLM was used as an adjunct to mammography in heterogeneously dense breasts and extremely dense breasts the sensitivity increased significantly," Dr. Qi stated. "This study suggests that in clinical practice, adding CTLM in dense breasts may be useful."

Following the study's presentation at RSNA, it will be released in China, where it will be used to help market the CTLM system throughout the country.

The CTLM system has completed registrations including the CE Mark, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM(R) system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM(R)) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth. The company is currently engaged in clinical trials for the FDA Pre-market approval application submission.

The FDA has determined that the Company's clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States.

For more information, visit our website: www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Imaging Diagnostic Systems

954-581-9800


'/>"/>
SOURCE Imaging Diagnostic Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
2. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
3. Imaging Diagnostic Systems Generates Cash From Building Sale
4. Imaging quantum entanglement
5. Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique
6. Elbit Medical Imaging Ltd. Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore, India
7. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
8. Elbit Medical Imaging Ltd. Announces Results of Its Annual General Meeting
9. Imaging Diagnostic Systems Expands Key Patent Coverage
10. Imaging Diagnostic Systems Exhibits CT Laser Breast Imaging Results at Major Italian Multidisciplinary Breast Cancer Meeting
11. New Optical Breast Cancer Imaging Technology Garners Cover Story in National Radiology Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 5, 2016  In the pharmaceutical industry the medical ... of launch activities including the identification and engagement of ... is especially high in the oncology therapeutic area where ... and the Role of Medical Affairs in Oncology Launch ... oncology therapies find better ways to utilize medical affairs ...
(Date:2/5/2016)... , February 5, 2016 Amarantus ... biotechnology company focused on developing products for Regenerative Medicine, ... Rare Pediatric Disease Designation (RPDD) from the US Food ... with MANF. MANF was previously granted orphan drug designation ... --> Amarantus BioScience Holdings, Inc. (OTCQB: ...
(Date:2/4/2016)... San Francisco, CA (PRWEB) , ... February 04, ... ... future of enterprise talent development and compliance training, today announced an interactive ... on Morf Playbook™. The RAPS (Regulatory Affairs Professional Society) accredited interactive course ...
(Date:2/4/2016)... 2016  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... Edward Lanphier , Sangamo,s president and chief executive ... Sangamo,s ZFP Therapeutic ® development programs and an ... ET on Thursday, February 11, 2016, at the Leerink ... conference is being held in New York ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of the bioinformatic market by reviewing the recent ... enabled tools that drive the field forward. Includes ... to: Identify the challenges and opportunities that ... providers and software solution developers, as well as ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 Technology ... service presents an analysis of the digital and computed ... Malaysia , and Indonesia ... current trends and market size, as well as regional ... by country and discusses market penetration and market attractiveness, ...
(Date:2/2/2016)... , Feb. 2, 2016  Based on its ... & Sullivan recognizes US-based Intelligent Retinal Imaging Systems ... Sullivan Award for New Product Innovation. IRIS, a ... North America , is poised to ... growing diabetic retinopathy market. The IRIS technology presents ...
Breaking Biology News(10 mins):